WEED.TO - Canopy Growth Corporation

Toronto - Toronto Delayed Price. Currency in CAD
32.15
-2.89 (-8.25%)
At close: 4:42PM EDT
Stock chart is not supported by your current browser
Previous Close35.04
Open34.00
Bid32.15 x 0
Ask32.20 x 0
Day's Range32.01 - 34.50
52 Week Range8.36 - 48.72
Volume5,075,994
Avg. Volume5,058,039
Market Cap7.09B
Beta3.61
PE Ratio (TTM)N/A
EPS (TTM)-0.40
Earnings DateAug 15, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.22
  • ACCESSWIRE6 hours ago

    3 Marijuana Stocks Canadian Investors Are Talking About

    CORAL GABLES, FL / ACCESSWIRE / August 14, 2018 / This year, Canada is expected to see a big boom come this October with the launch of its adult-use, recreational market. Market analysts have projected that Canada's legalized market could earn somewhere around $10.4 billion dollars once it gets started. TSX: WEED), and CV Sciences (CVSI) have caught attention during the months leading up to Canada's official launch for recreational retail sales.

  • ACCESSWIRE10 hours ago

    Could This $1/Share Healthcare Stock Soon Be Worth $9?

    Cardiac monitoring is a $32 billion market, and the companies that are successfully navigating this space with new REMOTE monitoring technology are seeing huge returns: IRTC is up 300% in 3 years, and BEAT is up 800% in 5 years. Biotricity (BTCY) is the most recent entrant into the remote monitoring space with their first FDA clearance in December of 2017. The launch of Bioflux, an advanced remote ECG monitoring device, is underway and Biotricity's first sales should emerge in the coming months after having signed some respected anchor clients.

  • CNW Group11 hours ago

    Canopy Growth extends existing commercial agreement

    SMITHS FALLS, ON , Aug. 14, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (WEED.TO) (CGC) has issued $2,500,000 in common shares of Canopy Growth in connection with the expansion of an existing commercial arrangement at a price per share equal to the 5-day volume weighted-average price of the Company's common shares on the TSX ending on [ August 10, 2018 ]. Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.

  • How Cannabis Stocks Fared Last Week
    Market Realistyesterday

    How Cannabis Stocks Fared Last Week

    Last week, the cannabis sector saw positive movement, and the Horizons Marijuana Life Sciences ETF (HMMJ) ended 1% higher between the closing on August 3 and the closing on August 10. The Emerging Marijuana Growers Index ETF (HMJR) also rose 2.6% over the same period, while the ETFMG Alternative Harvest ETF (MJ) fell by 82 basis points.

  • Another Major Beer Company Is Now Part of the Marijuana Craze
    Motley Fool2 days ago

    Another Major Beer Company Is Now Part of the Marijuana Craze

    Cannabis-infused beverages are all the rage.

  • Better Marijuana Stock: Canopy Growth Corporation vs. CannTrust Holdings Inc.
    Motley Fool2 days ago

    Better Marijuana Stock: Canopy Growth Corporation vs. CannTrust Holdings Inc.

    Which stock wins in a match-up between these two Canadian marijuana growers?

  • Motley Fool4 days ago

    How to Profit Off the Marijuana Industry

    There are lots of ways to invest in the growing marijuana market.

  • Spectrum Cannabis Introduces First of its Kind Catalyst Peer Mentorship Program
    CNW Group4 days ago

    Spectrum Cannabis Introduces First of its Kind Catalyst Peer Mentorship Program

    SMITHS FALLS, ON , Aug. 10, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (WEED.TO) (CGC) and its wholly owned subsidiary Spectrum Cannabis, together with Dr. Danial Schecter , Co-founder of the Cannabinoid Medical Clinic, today announced a new Catalyst Peer Mentorship Program ("Catalyst Program") which will link physicians from across the country with colleagues who possess advanced knowledge of the cannabis field in order to provide case-by-case support. Canada's regulatory framework for cannabis in Canada is evolving quickly, creating more and more interest from patients and healthcare practitioners in Canada .

  • Organigram’s Consensus Price Target Rose in August
    Market Realist5 days ago

    Organigram’s Consensus Price Target Rose in August

    Organigram (OGRMF) is among the top gainers compared to cannabis companies (HMMJ) such as Canopy Growth (WEED) (CGC) and Hydropothecary (HYYDF), both of which have delivered positive YTD returns. Organigram has returned about 14% YTD as of August 7. The consensus ratings on Organigram also remained unchanged month-over-month as of August 7.

  • Why Canopy Growth Corporation Stock Fell 10.1% in July
    Motley Fool5 days ago

    Why Canopy Growth Corporation Stock Fell 10.1% in July

    A competitor's IPO hit Canopy Growth hard last month.

  • PR Newswire5 days ago

    Canopy Growth Announces Further Consolidation of Latin America Assets with Full Acquisition of Spectrum Cannabis Chile

    This transaction brings Spectrum Cannabis Chile fully under the Canopy Growth umbrella and directly supports the Company's plans for development within the LATAM region which is home to more than 600 million people. Thanks to progressive regulations and Government support, Chile is known throughout Latin America as an ideal location for medical and pharmaceutical research.

  • Canopy Growth Announces Further Consolidation of Latin America Assets with Full Acquisition of Spectrum Cannabis Chile
    CNW Group5 days ago

    Canopy Growth Announces Further Consolidation of Latin America Assets with Full Acquisition of Spectrum Cannabis Chile

    This transaction brings Spectrum Cannabis Chile fully under the Canopy Growth umbrella and directly supports the Company's plans for development within the LATAM region which is home to more than 600 million people. Thanks to progressive regulations and Government support, Chile is known throughout Latin America as an ideal location for medical and pharmaceutical research.

  • What Analysts Recommend for Scotts Miracle-Gro
    Market Realist5 days ago

    What Analysts Recommend for Scotts Miracle-Gro

    The Scotts Miracle-Gro Company (SMG) reported its quarterly earnings on July 31. The company beat bottom-line estimates but missed top-line estimates. Find out what Market Realist recommends for Scotts Miracle-Gro and other stocks (HMLSF). The consensus rating on Scotts Miracle-Gro remained unchanged from the last month, which was similar to what we saw for Aphria (APHQF) and Canopy Growth (WEED) (CGC).

  • Investor's Business Daily6 days ago

    California's Hopes For The Legal Marijuana Industry Aren't Coming True

    Many people are still buying weed on the illicit market, thanks in part to steep markups and high taxes in legal pot shops, along with local restrictions, according to a survey from Eaze.

  • ACCESSWIRE6 days ago

    Pot Stocks Ramping Up For October 2018

    CORAL GABLES, FL / ACCESSWIRE / August 8, 2018 / The marijuana market has offered investors a new opportunity for what many are calling "the green rush". A new trend that investors are looking at is one of a mergers and acquisitions approach. Not only has it allowed cannabis businesses to expand a national footprint but also an international footprint mainly with companies in Canada.

  • What’s the Analyst Consensus on Aphria?
    Market Realist6 days ago

    What’s the Analyst Consensus on Aphria?

    Among the well-known cannabis stocks (SEED-TSE) such as Canopy Growth (WEED) and Aurora Cannabis (ACB) (ACBFF), Aphria (APHQF) has been one of the worst performers with a YTD loss of 52%. The consensus ratings on Aphria also remained unchanged from the last month. Out of the eight analysts, three maintained a “strong buy” recommendation on the stock, and four analysts maintained a “buy” on Aphria.

  • Analysts Remain Optimistic about Aurora Cannabis
    Market Realist6 days ago

    Analysts Remain Optimistic about Aurora Cannabis

    Aurora Cannabis stock (ACB) (ACBFF) has had a terrible performance over the last month. It is easy to see why investors are staying away from the cannabis sector (MJ) including Aphria (APHQF) and Cronos Group (CRON), both of which are down in the double digits YTD. The consensus rating on Aurora Cannabis is unchanged from last month.

  • Announcing the 3rd Annual Shindig in Smiths Falls
    CNW Group6 days ago

    Announcing the 3rd Annual Shindig in Smiths Falls

    SMITHS FALLS, ON , Aug. 8 , 2018­­­ /CNW/ - Tweed is pleased to announce the date for the third annual Shindig, the largest community and music event in Smiths Falls . Thankfully, the Town of Smiths Falls was willing to take a chance on us and welcomed Tweed with open arms. This wasn't an easy decision back then and the Shindig is our way of thanking our community, while giving our staff and their families a celebration for all the hard work they are pouring into recreational cannabis readiness.

  • Analyst Views in August: What’s the Outlook for Cannabis Stocks?
    Market Realist6 days ago

    Analyst Views in August: What’s the Outlook for Cannabis Stocks?

    Cannabis stocks have experienced significant declines since the beginning of this year. With that said, some big names such as Canopy Growth (WEED), Aurora Cannabis (ACB) (ACBFF), and Aphria (APHQF) have made heavy capital investments and are here to stay. In this series, we’ll discuss what analysts think about marijuana stocks (HMMJ) in terms of their ratings and price target.

  • Benzinga6 days ago

    Jim Cramer Weighs In On Canopy Growth, FMC Corp, Vivint Solar And More

    Jim Cramer said on CNBC's "Mad Money Lightning Round"  there are no more catalysts for Canopy Growth Corp (NYSE: CGC ) at the moment. We need to see what kind of beverages, candies, food and ...

  • PR Newswire6 days ago

    Canopy Growth announces clinical trial approval for the use of cannabis to treat anxiety in certain animals

    TORONTO and SMITHS FALLS, ON, Aug. 8, 2018 /PRNewswire/ - Canopy Growth Corporation (WEED.TO) (CGC) ("Canopy Growth" or the "Company") and its wholly owned subsidiary, Canopy Health Innovations Inc. ("Canopy Health" or "CHI") is pleased to announce that approval has been received from the Veterinary Drug Directorate of Health Canada to research the effectiveness of cannabidiol ("CBD") to treat anxiety in certain animals. The research will be conducted by Canopy Animal Health ("CAH"), a division of Canopy Health which focuses on developing cannabis-based healthcare products for companion animals. The CBD formulation will be produced by Canopy Growth in its GMP-certified production facility in Smiths Falls, Ontario.

  • Canopy Growth announces clinical trial approval for the use of cannabis to treat anxiety in certain animals
    CNW Group6 days ago

    Canopy Growth announces clinical trial approval for the use of cannabis to treat anxiety in certain animals

    TORONTO and SMITHS FALLS, ON , Aug. 8, 2018 /CNW/ - Canopy Growth Corporation (WEED.TO) (CGC) ("Canopy Growth" or the "Company") and its wholly owned subsidiary, Canopy Health Innovations Inc. ("Canopy Health" or "CHI") is pleased to announce that approval has been received from the Veterinary Drug Directorate of Health Canada to research the effectiveness of cannabidiol ("CBD") to treat anxiety in certain animals. The research will be conducted by Canopy Animal Health ("CAH"), a division of Canopy Health which focuses on developing cannabis-based healthcare products for companion animals. The CBD formulation will be produced by Canopy Growth in its GMP-certified production facility in Smiths Falls, Ontario .

  • Canopy Growth Corporation announces revised schedule for first quarter fiscal 2019 financial results conference call
    CNW Group7 days ago

    Canopy Growth Corporation announces revised schedule for first quarter fiscal 2019 financial results conference call

    Canopy Growth Corporation announces revised schedule for first quarter fiscal 2019 financial results conference call

  • Canopy Growth Corporation announces revised schedule for first quarter fiscal 2019 financial results conference call
    PR Newswire7 days ago

    Canopy Growth Corporation announces revised schedule for first quarter fiscal 2019 financial results conference call

    Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few.

  • Canopy Growth Strengthens Commitment to Cannabis-Based Medicines Through Completion of Canopy Health Innovations Acquisition
    CNW Group7 days ago

    Canopy Growth Strengthens Commitment to Cannabis-Based Medicines Through Completion of Canopy Health Innovations Acquisition

    TORONTO and SMITHS FALLS, ON , Aug. 7, 2018 /CNW/ - Canopy Growth Corporation (WEED.TO) (CGC) ("Canopy Growth" or the "Company") is pleased to announce that it has completed the previously announced acquisition of Canopy Health Innovations Inc. ("CHI"), including the subsidiary operations of Canopy Animal Health Inc. ("CAH"). The Company believes its strategy of integrating and aligning CHI's clinical platform with the international work of Spectrum Cannabis, will accelerate its comprehensive research programs, build evidence around Canopy products and formulations and ultimately improve patient access to medical cannabis globally. "Canopy Growth continues to expand its medical cannabis leadership around the globe with an ecosystem that includes world class production and infrastructure, patient and healthcare practitioner education, and robust clinical research," said Mark Zekulin , President & Co-CEO, Canopy Growth.